Our progress

In recent years remarkable progress has been made in melanoma research, which has led to the introduction of the first treatments to prolong life in patients with advanced disease: both targeted treatments and immune therapies. Although genomics has yielded a wealth of information on the genetic alterations in melanoma tumours, further characterisation is urgently needed in order to predict responses to combinations of targeted therapies and MELGEN will address this need. The dramatic responses seen in melanoma patients to immunotherapies indicate that immune responses to melanoma are crucial, and we need to better understand what predicts response in order to improve treatment strategies, particularly in the adjuvant setting. MELGEN will explore host/tumour interactions and detect biomarkers of response to treatment. The academic centres and several commercial partners of this network will address these research questions using unique samples and data sets and the most sophisticated technologies, including genomic and transcriptomic analyses, functional genetic screens, CRISPR genome editing, iPS cell-based disease models, liquid biopsy technology, developmental statistics and bioinformatics.


Our PhD students are
based all over europe

The PhD students will be based in 7 research groups in Europe. The training network is coordinated by the University of Leeds in the UK, where three students will be based. It is funded by a Marie Skłodowska-Curie  Early Training Network (ETN) grant. Two students will be based at the Leiden University Medical Center in the Netherlands, three at the Universitåtsklinikum in Essen, Germany, three at Lunds Universitet in Sweden, two at the Genome Research Limited at the Wellcome Trust Sanger Institute in the UK, and two at the University of Oslo in Norway. Two students will be funded by the Swiss Government but as part of the ETN.

Find out more about our graduates


The students and the host research groups will be benefit from the experience of 4 additional institutions/companies. These are known as partners in the ETN. The students will benefit from experience gained through secondments at some of these partner institutions.

The 4 partners are:,

Digitronix based in Leeds, UK

Eagle Genomics Ltd based in Cambridge, UK

ServiceXS based in Leiden, the Netherlands

The Wistar Institute, University of Pennsylvania, Philadelphia, USA